Alan J. Lewis

Alan J.
Lewis currently works at Batu Biologics, Inc., as Chairman from 2015, NeuraMetrix, Inc., as Chairman, Rincon Pharmaceuticals, Inc., as Director, Sosei Co. Ltd., as Director, Scancell Ltd., as Director, BIOCOM, as Director, Targazyme, Inc., as Director from 2010, Capella Therapeutics, Inc., as Director, and Habit DX, Inc., as Director.
Dr. Lewis also formerly worked at Signal Pharmaceuticals, Inc., as President & Chief Executive Officer from 1994 to 2000, Medistem, Inc., as Chief Executive Officer & Director from 2012 to 2014, ViaCyte, Inc., as President & Chief Executive Officer in 2008, Ambit Biosciences Corp., as President, Chief Executive Officer & Director in 2011, DiaVacs, Inc., as President, Chief Executive Officer & Director, Novocell, Inc. (Old), as President & Chief Executive Officer from 2006 to 2008, Juvenile Diabetes Research Foundation Ltd., as President & Chief Executive Officer in 2010, Signal Therapeutics, Inc., as Chief Executive Officer, Cytochroma, Inc., as Chairman, LymphoSign, Inc., as Chairman, Novation Pharmaceuticals, Inc., as Chairman, BioMarin Pharmaceutical, Inc., as Independent Non-Executive Director from 2014 to 2020, Discovery Partners International, Inc., as Director, Biotica Technology Ltd., as Non-Executive Director in 2013, Sosei Group Corp., as Non-Executive Director, Scancell Holdings Plc, as Non-Executive Director from 2016 to 2020, Cellastra, Inc., as Director, Assembly Biosciences, Inc., as Independent Director from 2015 to 2020, Yale University, as Research Associate from 1972 to 1973, Celgene Research & Development Co. LLC, as President from 2000 to 2006, Wyeth-Ayerst Research, as Vice President-Research from 1979 to 1994, and Wyeth Laboratories, Inc., as Principal.
Dr. Lewis received his undergraduate degree from The University of Southampton and doctorate degree from The University of Wales.